2024 WBDR Impact Report published

2024 WBDR Impact Report published

The World Federation of Hemophilia (WFH) is proud to publish the 2024 World Bleeding Disorders Registry (WBDR) Impact Report, marking the seventh year of this important global initiative. The WBDR is designed to systematically collect real-world clinical data on people with hemophilia (PWH) and people with von Willebrand disease (PwVWD), and the report shows that the registry is playing an ever-increasing role in shaping care, research, and advocacy worldwide for our community.

Also available in: Français Español

As of December 31, 2024, the WBDR includes data from over 17,000 individuals across 124 hemophilia treatment centres (HTCs) in 47 countries. This growing body of data offers insights into care patterns, disparities, and treatment challenges experienced by PWH and PwVWD.

The 2024 WBDR Impact Report details a year of significant progress in data collection, program development, and global collaboration. It highlights how WBDR data is being used to identify gaps in care, inform research, and strengthen national and international advocacy efforts aimed at improving health outcomes and promoting equity.

Here are some key facts pulled from the report:

The WBDR continues to serve as a global benchmark for understanding clinical practices and addressing inequalities in care, and its success is due to the commitment of the healthcare providers, individuals with bleeding disorders, and treatment centres who contributed their time and data to this important endeavour.

The WFH encourages additional HTCs to join the WBDR initiative so that we can continue to expand this important offering for our community. By doing so, they will help support our shared mission of Treatment for All.

To read the WBDR Impact Report, please click here. To find out more about the WBDR, pleased click here.

The WBDR is made possible by the support of our visionary partner Sobi, and our collaborating partners Grifols, F. Hoffman-La Roche, Novo Nordisk, Pfizer and Sanofi.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.